SCHEMBL4058461

SCHEMBL4058461

FC(F)(F)c1cccc(-c2cnc3nc(-c4ccccc4)[nH]c3c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN2A Q99250 2/20 0.56
NPBWR1 P48145 2/20 0.54
AURKA O14965 3/20 0.53
MAPK13 O15264 1/20 0.53
RAF1 P04049 1/20 0.53
MAPK9 P45984 1/20 0.53
MAPK12 P53778 1/20 0.53
MAPK11 Q15759 1/20 0.53
MAPK14 Q16539 1/20 0.53
DGAT1 O75907 2/20 0.52
KCNH2 Q12809 2/20 0.52
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
THRB P10828 1/20 0.50
CYP2C9 P11712 1/20 0.50
PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4057030 0.95 SCN2A (0.53) SCN2ANPBWR1AURKAMAPK13RAF1
SCHEMBL4059653 0.88 HTT (0.55) SCN2ANPBWR1AURKAKDM4EMEN1
SCHEMBL4053038 0.87 AURKA (0.49) SCN2ANPBWR1AURKAMAPK13RAF1
SCHEMBL4059872 0.87 AURKA (0.61) AURKAGRIN1GRIN2B
SCHEMBL4050873 0.85 AURKA (0.58) SCN2AAURKAKDM4EMEN1NPC1
SCHEMBL4059131 0.83 AURKA (0.56) AURKANPC1CYP3A4RAB9APDPK1
SCHEMBL4053263 0.83 PDE5A (0.52) SCN2AAURKAGRIN1GRIN2B
SCHEMBL4056702 0.83 AURKA (0.44) SCN2ANPBWR1AURKAMAPK14KDM4E
SCHEMBL4058862 0.82 CLK1 (0.46) SCN2AAURKAKDM4EMEN1NPC1
SCHEMBL4051797 0.82 AURKA (0.44) SCN2AAURKAKDM4EMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B SCN2A 2825/4885NPBWR1 1615/4885AURKA 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.